Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Merus NV MRUS

Healthcare Biotechnology
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MRUS)

Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

GlobeNewswire June 3, 2024

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

GlobeNewswire June 2, 2024

Merus Announces Pricing of Upsized Public Offering of Common Shares

GlobeNewswire May 29, 2024

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2024

Merus N.V. Announces Proposed Public Offering of Common Shares

GlobeNewswire May 28, 2024

Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

GlobeNewswire May 28, 2024

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

GlobeNewswire May 23, 2024

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

GlobeNewswire May 23, 2024

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

GlobeNewswire May 13, 2024
View More News ››

Opinion & Analysis (NDAQ:MRUS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MRUS)

MRUS Price Target Alert: $84.00. Issued by BMO Capital

Breaking News: $MRUS MRUS Price Target Alert: $84.00. Issued by BMO Capital2024-05-28 14:00:08 ET Etzer Darout from BMO Capital issued a...
whytestocks - May 28, 2024
View more Bullboard ››

Viva Gold Corp.

Viva Gold Corp.

Viva Gold Corp. is a Canada-based gold exploration and development company, The Company’s business is the acquisition ...
View More »